دورية أكاديمية
أعرض في EDS

BmooMPα-I, a Metalloproteinase Isolated from Bothrops moojeni Venom, Reduces Blood Pressure, Reverses Left Ventricular Remodeling and Improves Cardiac Electrical Conduction in Rats with Renovascular Hypertension.

التفاصيل البيبلوغرافية
العنوان: BmooMPα-I, a Metalloproteinase Isolated from Bothrops moojeni Venom, Reduces Blood Pressure, Reverses Left Ventricular Remodeling and Improves Cardiac Electrical Conduction in Rats with Renovascular Hypertension.
المؤلفون: Estrada JEC; Laboratory of Pharmacology and Toxicology of Cardiovascular System, Institute of Biological Sciences, Federal University of Pará, Belém 66075-110, PA, Brazil.; Laboratory of Hemostasis and Venoms, Institute of Medical Biochemistry Leopoldo de Meis, Federal University of Rio de Janeiro, Rio de Janeiro 21941-902, RJ, Brazil., Rodrigues KE; Laboratory of Pharmacology and Toxicology of Cardiovascular System, Institute of Biological Sciences, Federal University of Pará, Belém 66075-110, PA, Brazil., Maciel A; Center of Study of Biomolecules Applied in Medicine (CEBio), Oswaldo Cruz Foundation (Fiocruz Rondônia), Federal University of Rondônia, Porto Velho 76812-245, RO, Brazil., Bannwart CM; Laboratory of Pharmacology and Toxicology of Cardiovascular System, Institute of Biological Sciences, Federal University of Pará, Belém 66075-110, PA, Brazil., Dias WF; Laboratory of Pharmacology and Toxicology of Cardiovascular System, Institute of Biological Sciences, Federal University of Pará, Belém 66075-110, PA, Brazil., Hamoy M; Laboratory of Pharmacology and Toxicology of Natural Products, Institute of Biological Sciences, Federal University of Pará, Belém 66075-110, PA, Brazil., Zingali RB; Laboratory of Hemostasis and Venoms, Institute of Medical Biochemistry Leopoldo de Meis, Federal University of Rio de Janeiro, Rio de Janeiro 21941-902, RJ, Brazil., Soares AM; Center of Study of Biomolecules Applied in Medicine (CEBio), Oswaldo Cruz Foundation (Fiocruz Rondônia), Federal University of Rondônia, Porto Velho 76812-245, RO, Brazil.; São Lucas University Center, Porto Velho 76805-846, RO, Brazil., Ribeiro CHMA; Laboratory of Hematology, Faculty of Pharmacy, Institute of Health Science, Federal University of Pará, Belém 66075-110, PA, Brazil., Gerlach RF; Department of Basic and Oral Biology, Faculty of Dentistry of Ribeirao Preto, University of São Paulo (FORP/USP), Ribeirao Preto 14040-904, SP, Brazil., Monteiro MC; Laboratory of Clinical Immunology and Oxidative Stress, Pharmacy Faculty, Institute of Health Science, Federal University of Pará, Belém 66075-110, PA, Brazil., Prado AF; Laboratory of Pharmacology and Toxicology of Cardiovascular System, Institute of Biological Sciences, Federal University of Pará, Belém 66075-110, PA, Brazil.
المصدر: Toxins [Toxins (Basel)] 2022 Nov 05; Vol. 14 (11). Date of Electronic Publication: 2022 Nov 05.
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: MDPI Country of Publication: Switzerland NLM ID: 101530765 Publication Model: Electronic Cited Medium: Internet ISSN: 2072-6651 (Electronic) Linking ISSN: 20726651 NLM ISO Abbreviation: Toxins (Basel) Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Basel : MDPI
مواضيع طبية MeSH: Bothrops* , Crotalid Venoms*/pharmacology , Hypertension, Renovascular*/drug therapy, Animals ; Rats ; Blood Pressure ; Heart Rate ; Metalloproteases/pharmacology ; Rats, Wistar ; Ventricular Remodeling
مستخلص: BmooMPα-I has kininogenase activity, cleaving kininogen releasing bradykinin and can hydrolyze angiotensin I at post-proline and aspartic acid positions, generating an inactive peptide. We evaluated the antihypertensive activity of BmooMPα-I in a model of two-kidney, one-clip (2K1C). Wistar rats were divided into groups: Sham, who underwent sham surgery, and 2K1C, who suffered stenosis of the right renal artery. In the second week of hypertension, we started treatment (Vehicle, BmooMPα-I and Losartan) for two weeks. We performed an electrocardiogram and blood and heart collection in the fourth week of hypertension. The 2K1C BmooMPα-I showed a reduction in blood pressure (systolic pressure: 131 ± 2 mmHg; diastolic pressure: 84 ± 2 mmHg versus 174 ± 3 mmHg; 97 ± 4 mmHg, 2K1C Vehicle, p < 0.05), improvement in electrocardiographic parameters (Heart Rate: 297 ± 4 bpm; QRS: 42 ± 0.1 ms; QT: 92 ± 1 ms versus 332 ± 6 bpm; 48 ± 0.2 ms; 122 ± 1 ms, 2K1C Vehicle, p < 0.05), without changing the hematological profile (platelets: 758 ± 67; leukocytes: 3980 ± 326 versus 758 ± 75; 4400 ± 800, 2K1C Vehicle, p > 0.05), with reversal of hypertrophy (left ventricular area: 12.1 ± 0.3; left ventricle wall thickness: 2.5 ± 0.2; septum wall thickness: 2.3 ± 0.06 versus 10.5 ± 0.3; 2.7 ± 0.2; 2.5 ± 0.04, 2K1C Vehicle, p < 0.05) and fibrosis (3.9 ± 0.2 versus 7.4 ± 0.7, 2K1C Vehicle, p < 0.05). We concluded that BmooMPα-I improved blood pressure levels and cardiac remodeling, having a cardioprotective effect.
References: Naunyn Schmiedebergs Arch Pharmacol. 2011 Jan;383(1):35-44. (PMID: 21058008)
Circ Res. 2021 Apr 2;128(7):993-1020. (PMID: 33793335)
Braz J Med Biol Res. 2018 Sep 03;51(11):e7338. (PMID: 30183974)
Circulation. 1999 Dec 7;100(23):2305-7. (PMID: 10587332)
Hypertens Res. 2013 Sep;36(9):770-5. (PMID: 23676847)
Clin Exp Hypertens (1978). 1978;1(1):67-86. (PMID: 158496)
Bratisl Lek Listy. 1996 Sep;97(9):543-9. (PMID: 8948150)
Pharmaceutics. 2021 Sep 28;13(10):. (PMID: 34683872)
FEBS J. 2011 Dec;278(23):4544-76. (PMID: 21470368)
Peptides. 2016 Nov;85:46-55. (PMID: 27628189)
Biomolecules. 2021 Apr 16;11(4):. (PMID: 33923477)
Heart. 2015 Sep;101(17):1406-11. (PMID: 26060120)
J Venom Anim Toxins Incl Trop Dis. 2018 Dec 13;24:38. (PMID: 30564275)
Pharmacol Res. 1997 Jun;35(6):517-22. (PMID: 9356201)
Biochim Biophys Acta. 2014 Mar;1844(3):545-52. (PMID: 24373874)
J Electrocardiol. 2014 Sep-Oct;47(5):589-92. (PMID: 25042854)
Free Radic Biol Med. 2013 Dec;65:47-56. (PMID: 23806385)
Cardiovasc Res. 1996 Apr;31(4):546-54. (PMID: 8689646)
Int J Cardiol. 2013 Aug 20;167(4):1199-205. (PMID: 22483258)
Am Heart J. 2003 May;145(5):919-25. (PMID: 12766755)
J Bras Nefrol. 2013 Oct-Dec;35(4):273-8. (PMID: 24402107)
Redox Biol. 2018 Sep;18:181-190. (PMID: 30029165)
Circulation. 2009 May 12;119(18):2480-9. (PMID: 19398663)
Br J Pharmacol. 2010 May;160(1):77-87. (PMID: 20331602)
Circulation. 2004 Mar 9;109(9):1168-71. (PMID: 14981002)
Int J Cardiol. 2013 Apr 30;165(1):165-73. (PMID: 21917342)
Cardiovasc Res. 2000 May;46(2):324-31. (PMID: 10773237)
J Cardiovasc Electrophysiol. 2001 Jul;12(7):830-5. (PMID: 11469438)
Toxicon. 2008 Mar 15;51(4):574-84. (PMID: 18187176)
J Physiol. 2006 Dec 15;577(Pt 3):1053-65. (PMID: 17038430)
J Biol Chem. 2009 Jul 24;284(30):20022-33. (PMID: 19491403)
Exp Physiol. 2005 Jul;90(4):621-6. (PMID: 15833755)
Eur Heart J. 1990 Dec;11 Suppl I:114-23. (PMID: 2092980)
Circulation. 2015 Apr 7;131(14):1247-59. (PMID: 25637629)
Hypertension. 1998 Jul;32(1):84-8. (PMID: 9674642)
Int J Proteomics. 2013;2013:135709. (PMID: 24062950)
Am J Hypertens. 1996 Nov;9(11):1062-7. (PMID: 8931830)
J Biomol Tech. 2011 Jul;22(2):67-73. (PMID: 21738439)
Free Radic Biol Med. 2014 Aug;73:308-17. (PMID: 24933619)
Nat Med. 2001 Nov;7(11):1236-40. (PMID: 11689889)
Pharmaceutics. 2022 Jul 30;14(8):. (PMID: 36015225)
Circ Res. 2021 Apr 2;128(7):969-992. (PMID: 33793333)
Anatol J Cardiol. 2015 Jan;15(1):33-9. (PMID: 25179883)
Nat Rev Nephrol. 2020 Apr;16(4):223-237. (PMID: 32024986)
Clin Exp Hypertens. 2021 Aug 18;43(6):572-578. (PMID: 33866872)
Biochimie. 2020 Dec;179:54-64. (PMID: 32946987)
Clin Exp Pharmacol Physiol. 2020 Dec;47(12):1965-1977. (PMID: 32688435)
J Cardiovasc Electrophysiol. 1997 Aug;8(8):887-94. (PMID: 9261715)
Toxicon. 2012 Mar 15;59(4):516-23. (PMID: 21835190)
Eur J Pharmacol. 2010 Sep 1;641(2-3):187-92. (PMID: 20553920)
Circ Res. 2019 Mar 29;124(7):1061-1070. (PMID: 30920924)
Pharmaceuticals (Basel). 2022 Jul 25;15(8):. (PMID: 35893744)
Aging Dis. 2021 Feb 1;12(1):116-131. (PMID: 33532132)
Hypertens Res. 2004 Nov;27(11):865-75. (PMID: 15824469)
Cytometry A. 2011 Jan;79(1):77-83. (PMID: 20814884)
Exp Mol Pathol. 2013 Feb;94(1):1-9. (PMID: 23073243)
Hypertension. 2009 Sep;54(3):575-82. (PMID: 19581512)
Cardiovasc Res. 2000 Mar;45(4):900-12. (PMID: 10728416)
Circ Arrhythm Electrophysiol. 2016 Jul;9(7):. (PMID: 27390211)
Med J Aust. 1990 Nov 19;153(10):595-9, 602-3. (PMID: 2233433)
JACC Heart Fail. 2014 Jun;2(3):260-8. (PMID: 24952693)
Circ Res. 1960 Jan;8:129-34. (PMID: 14441202)
Sheng Li Xue Bao. 2001 Aug;53(4):281-5. (PMID: 11930206)
J Pharm Biomed Anal. 2013 Jan 25;73:35-43. (PMID: 22571953)
Molecules. 2019 Jul 31;24(15):. (PMID: 31370142)
Braz J Med Biol Res. 2020 Jun 26;53(8):e9493. (PMID: 32609261)
Biochem Biophys Res Commun. 2001 Mar 9;281(4):1012-8. (PMID: 11237764)
J Cardiovasc Pharmacol. 1998 Oct;32(4):601-7. (PMID: 9781928)
JAMA. 2013 Mar 6;309(9):896-908. (PMID: 23462786)
Transl Res. 2019 Jul;209:138-155. (PMID: 30986384)
فهرسة مساهمة: Keywords: arrhythmia; cardioprotective effect; fibrosis; remodeling; snake venom
المشرفين على المادة: 0 (Crotalid Venoms)
EC 3.4.- (Metalloproteases)
تواريخ الأحداث: Date Created: 20221110 Date Completed: 20221114 Latest Revision: 20230125
رمز التحديث: 20240628
مُعرف محوري في PubMed: PMC9697896
DOI: 10.3390/toxins14110766
PMID: 36356016
قاعدة البيانات: MEDLINE
الوصف
تدمد:2072-6651
DOI:10.3390/toxins14110766